A novel bone resorption inhibitor, A-75943, was isolated from Streptomyces sp. SANK 61296. Its structure was determined to be (1"S, 2'R, 3"S, 4S', 5"S)-2-[(3",5"-dimethyl-2"-oxocyclohexan-1"-yl)-6'-oxotetrahydropyran- 4 In the course of a program to discover novel drugs or lead compounds thereof, for prevention and treatment of osteoporosis and hypercalcemic diseases, we extensively tested fermentation broths or their lipophilic extracts for in vitro inhibition of pit formation in an osteoclast-induced bone resorption assay using mouse unfractionated bone cells and found that a lipophilic extract of a fermentation supernatant of Streptomyces sp., SANK 61296, potently inhibited bone resorption.
We herein report on fermentation, isolation, structure elucidation, and in vitro and in vivo bone resorption inhibitory activities of A-75943 (1) and also describe the chemical conversion of cycloheximide to 1.
Identification of the Producing Strain
The producing organism, strain A-75943, was isolated from a soil sample collected on Mt. Tsukuba, Ibaraki Prefecture, Japan. Methods and media described by the International Streptomyces Project (ISP)2) and WAKS-MAN3) were used to determine most of the cultural and physiological characteristics. For morphological observation, a light microscope and a scanning electron microscope (5-4500, Hitachi) were used. Whole-cell hydrolysates were analyzed by the method of HASEGAWA et al.4). Strain A-75943 grew relatively well on both natural and synthetic media, and formed spiral spore chains at the tips of the aerial mycelia. Spore surfaces were smooth. The mature spore chains comprised more than 50 spores each (Fig. 1) . Neither melanoid pigment nor soluble pigment was produced. The cultural characteristics in various agar media are shown in Table  1 . The physiological properties are shown in Table 2 . L,L-Diaminopimelic acid was found in the cell wall, and no characteristic sugar component was detected in the whole-cell hydrolysates, indicating that the cell wall type was I/NC. Based on the taxonomic characteristics described above, strain A-75943 was identified as concomitant treatment with A-75943 (1) in these rats suppressed these changes; in the experiment-1, the serum Ca2+ concentrations in each dose were lowered in a dose-dependent manner as shown in Table 4 and Fig . 6 , and the decreases of BMD in each dose were also inhibited in a dose-dependent manner as shown in Table   Fig Resorbed lacunae were measured under a light microscope by counting the number of pits.
In Vivo Bone Resorption Inhibitory Effect The in vivo bone resorption inhibitory effect of A-75943
(1) was examined in Ro-136298-treated thyroparathyroidectomized (TPTX) rats, an experimental model of accelerated bone resorption8). Male 8-week-old Wistar Imamichi rats were thyroparathyroidectomized, and animals with plasma Ca2+ levels below 8mg/dl measured on the 3rd day following TPTX were selected for the experiment. These animals were divided into four groups (six rats in each group) and three groups of rats received a subcutaneous injection of Ro-136298, at a dose of 6th, and 8th day following TPTX. Animals in the control group received vehicle alone. Among three Ro-136298-treated groups, two groups received a concomitant daily subcutaneous administration of A-75943 (1) (3 and 30mg/kg), and the remaining group received vehicle from the 4th to the 10th day following TPTX. Blood was taken for plasma Ca2+ measurement on the 8th and 10th day. The animals were sacrificed on day 10. The femurs of each animal were removed and cleaned for bone mineral density (BMD) measurement by dual energy X-ray absorptiometry (DCS600R).
